1. Introduction {#s0005}
===============

Triterpenoids naturally occurring in the plant kingdom are one of the largest groups of natural products [@bb0005]. Until now, it has been reported that some of them exhibited a wide spectrum of biological activities, such as antitumor, antiviral, antidiabetic, anti-inflammatory, antimicrobial, hepatoprotective, cardiotonic, gastroprotective and analgesic effects, *etc.* [@bb0010], [@bb0015], [@bb0020]. More importantly, some triterpenoids or their derivatives are promising candidates or lead compounds for the development of future drugs due to their therapeutic potential [@bb0015], [@bb0025], [@bb0030].

The plants in *Tripterygium* genus of family Celastraceae are well known for a rich source of triterpenoids. Many triterpenes isolated from this genus, showed various promising bioactivities. Celastrol, a quinone methide triterpene isolated from *Tripterygium* plants [@bb0035], [@bb0040], [@bb0045], exhibited potent anticancer activity against a variety of human cancer cell lines [@bb0020], anti-inflammatory [@bb0050] and neuroprotective effects [@bb0050], [@bb0055]. Recently, it has been reported to be used as a powerful anti-obesity agent [@bb0060]. In addition, celastrol, pristimerin, tingenone, iguesterin and dihydrocelastrol showed SARS-CoV 3CL^pro^ inhibitory activity [@bb0065].

*Tripterygium regelii*, which is distributed throughout northeast China, Korea and Japan [@bb0070], has been used as a folk medicine in China for the treatment of rheumatoid arthritis, jaundice, swelling, *etc.* [@bb0075]. A few previous studies [@bb0045], [@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100] have shown that terpenoids were the principal constituents of *T. regelii*. Recently, we have reported the isolation of twelve new dihydro-*β*-agarofuran sesquiterpenoids from its stems [@bb0105] *.* As a part of our ongoing phytochemical investigation, three new triterpenoids and twenty known analogues were isolated and characterized from the stems of *T. regelii*. Herein, we reported the isolation and characterization of three novel triterpenoids (**1**--**3**) and twenty known compounds (**4**--**23**), as well as a cytotoxic evaluation of nine selected triterpenes against human breast cancer MCF-7 cells.

2. Experimental {#s0010}
===============

2.1. General experimental procedures {#s0015}
------------------------------------

Optical rotations and ultraviolet (UV) spectra were measured using a Rudolph Research Analytical Autopol I automatic polarimeter and a Beckman Coulter DU® 800 spectrophotometer (USA), respectively. HRMS spectra were performed on an Agilent 6230 electrospray ionization (ESI) time--of--flight (TOF) mass spectrometer (USA). Nuclear magnetic resonance (NMR) spectra were acquired with a Bruker Ascend 600 NMR spectrometer in CDCl~3~ and pyridine-*d* ~*5*~ using tetramethylsilane (TMS) as an internal reference. Chemical shifts were given in *δ* (ppm), and coupling constants (*J*) were expressed in hertz (Hz). Preparative HPLC was carried out on a Waters liquid chromatography system equipped with 1525 Binary HPLC Pump and 2489 UV/ Visible detector using a Waters Xbridge Prep C~8~ column (10 × 250 mm, 5 μm). Semi-preparative HPLC was conducted on an Agilent 1100 liquid chromatography system coupled with a quaternary pump and a diode array detector (DAD) using a Waters Xbridge Prep C~18~ column (10 × 250 mm, 5 μm). Silica gel (40--60 μm, Grace, USA) and Bondapak Waters ODS (40--63 μm, Waters, USA) were used for column chromatographies. Thin layer chromatography (TLC) used to monitor fractions was performed on precoated silica gel 60 F~254~ plates and TLC silica gel 60 RP-18 F~254S~ plates (200 μm thick, Merck KGaA, Germany). Spots on the TLC were visualized by UV light (254 nm) or heating after spraying with 5% H~2~SO~4~ in ethanol.

2.2. Plant material {#s0020}
-------------------

The stems of *T. regelii* were collected in October 2012, from Changbai Mountain in Jilin province, People\'s Republic of China, and were identified by Dr. Liang Xu (Liaoning University of Traditional Chinese Medicine, Dalian, China). A voucher specimen (No. MUST − TR201210) has been deposited at State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China.

2.3. Extraction and isolation {#s0025}
-----------------------------

The dried and ground stems of *T. regelii* (8.0 kg) were extracted with methanol (64 L × 3) under ultrasonic assistance at room temperature for 1 h. After evaporation of the solvent under reduced pressure, a dark brown residue was suspended in H~2~O, and then sequentially partitioned with *n*-hexane, ethyl acetate (EtOAc) and *n*-butanol. The EtOAc-soluble extract (150.0 g) was subjected to column chromatography over silica gel eluting with PE--acetone (100:0--35:65, *v*/v) to yield thirteen fractions (Fr.1--Fr.13).

The fraction Fr.5 (5.0 g) was separated by a silica gel column using a gradient of n-hexane--EtOAc (100:0--50:50, *v*/v) to produce eight fractions (Fr.5--1 − Fr.5--8). The fraction Fr.5--7 (71.1 mg) was chromatographed over an ODS column with a gradient of CH~3~OH − H~2~O (60:40--100:0, *v*/v) to afford compound **8** (5.0 mg). The fraction Fr.7 (5.4 g) was subjected to an ODS column using a gradient system of CH~3~OH − H~2~O (50:50--100:0, *v*/v) to afford nine fractions (Fr.7--1 − Fr.7--9). The fraction Fr.7--5 (120.5 mg) was further separated by preparative HPLC using an isocratic solvent system of CH~3~CN − H~2~O (70:30, *v*/v) as mobile phase to yield compound **7** (1.5 mg). The fraction Fr.8 (5.0 g) was subjected to an ODS column with a gradient condition of CH~3~OH − H~2~O (50:50--100:0) to product nine fractions (Fr.8--1--Fr.8--9). The fraction Fr.8--3 (264.9 mg) was purified by semi-preparative HPLC using CH~3~CN − H~2~O (68:32, *v*/v) as mobile phase to give compound **6** (4.3 mg). The fraction Fr.8--4 (500.9 mg) was isolated by preparative HPLC using CH~3~CN − H~2~O (70:30, *v*/v) as mobile phase to give compounds **19** (1.5 mg), **20** (2.1 mg) and **12** (2.0 mg). The fraction Fr.8--6 (425.1 mg) was subjected to a silica gel column with a solvent system of PE − EtOAc (90:10--65:35, *v*/v), and purified using an ODS column with a gradient of MeOH − H~2~O (70:30--100:0, *v*/v) to give compound **5** (60.0 mg). Compound **21** (28.3 mg) was obtained from fraction Fr.8--8 (80.5 mg) by using a silica gel column eluted sequentially with PE − EtOAc (90:10--60:40) solvent system. The fraction Fr.11 (5.5 g) was fractionated over an ODS column with a gradient system of CH~3~OH − H~2~O (40:60--90:10, *v*/v) to obtain fifteen fractions (Fr.11--1 − Fr.11--15). Fraction Fr.11--12 (261.0 mg) was separated by semi-preparative HPLC using CH~3~CN − H~2~O (60:40, *v*/v) as solvent system to furnish compound **11** (1.5 mg). The fraction Fr.11--13 (950.1 mg) was chromatographed on a silica gel column with a gradient of PE − EtOAc (70:30--0:100, *v*/v) to afford ten fractions (Fr.11--13-1 − Fr.11--13-10). The fraction Fr.11--13-1 (150.0 mg) was separated by semi-preparative HPLC using CH~3~CN − H~2~O (76:24, *v*/v) as solvent system to give compounds **1** (1.0 mg), **2** (0.6 mg) and **10** (30.0 mg). Compound **4** (2.0 mg) was purified by silica gel column using a gradient of CHCl~3~  − CH~3~OH (100:0--95:5, *v*/v) from fraction Fr.11--13-2 (100.0 mg). Then, the fraction Fr.11--13-6 (217.2 mg) was subjected to a silica gel column using a gradient elution of CHCl~3~  − CH~3~OH (100:0--90:10, *v*/v) to yield compound **13** (20.0 mg) and subfractions (Fr.11--13--6-1 − Fr.11--13--6-4). The subfractions Fr.11--13--6-2 and Fr.11--13--6-4 were isolated by semi-preparative HPLC using CH~3~CN − H~2~O (37:63 and 39:61, *v*/v, respectively) as mobile phase to afford compounds **18** (2.1 mg) and **23** (2.1 mg), respectively. The fraction Fr.11--13-9 (367.0 mg) was purified by semi-preparative HPLC using CH~3~CN − H~2~O (65:35, *v*/v) as eluting solvent to give compound **22** (2.0 mg). Compounds **14** (6.1 mg) and **17** (2.0 mg) were obtained by preparative HPLC using CH~3~CN − H~2~O (65:35, *v*/v) as mobile phase from fraction Fr.11--14 (200.0 mg). The fraction 11--15 (367.0 mg) was separated by a silica gel column using a PE-EtOAc (80:20--30:70  *v*/v) gradient solvent system to give compounds **15** (2.6 mg), **16** (9.3 mg), and six subfractions (Fr.11--15-3--Fr.11--15-8). Then, compounds **3** (3.0 mg) and **9** (5.0 mg) were isolated by an ODS columns with a gradient elution of CH~3~OH − H~2~O (40:60--100:0, *v*/v) from the subfractions Fr.11--15-7 (38.9 mg) and Fr.11--15-8 (40.0 mg), respectively.

2.4. Spectroscopic data {#s0030}
-----------------------

Triregelolide A (**1**): white amorphous powder; \[*α*\]^21^ ~D~  + 157.8 (*c* 0.50, MeOH); UV (MeOH) *λ* ~max~ (log *ε*) 236 (3.65), 360 (3.88) nm; ^1^H (CDCl~3~, 600 MHz) and ^13^C (CDCl~3~, 150 MHz) NMR data, see [Table 1](#t0005){ref-type="table"} ; HRESIMS *m/z* 467.2812 \[M − H\]^−^ (calcd for C~29~H~39~O~5~, 467.2803).Table 1^1^H (600 MHz) and ^13^C (150 MHz) NMR spectroscopic data for **1**--**3.**Table 1Position1 ^a^2 ^a^3 ^b^*δ*~H~ (*J* in Hz)*δ*~C~, type*δ*~H~ (*J* in Hz)*δ*~C~, type*δ*~H~ (*J* in Hz)*δ*~C~, type15.81 (1H, d, 1.2)110.3, CH5.79 (1H, d, 1.8)110.2, CH1.23 (1H, dd, 12.0, 9.6) ^*c*^47.0, CH~2~2.24 (1H, dd, 12.0, 4.2)2163.8, C163.8, C4.13 (1H, td, 9.6, 4.2)68.6, CH33.39 (1H, d, 9.6)83.8, CH4103.8, C105.6, C39.8, C5125.9, C125.3, C0.98 (1H, dd, 12.1, 1.9)56.0, CH66.32 (1H, dd, 6.6, 1.2)126.6, CH6.29 (1H, dd, 6.6, 1.8)126.0, CH1.55 (1H, m) ^*c*^17.9, CH~2~1.71 (1H, m) ^*c*^75.98 (1H, d, 6.6)115.7, CH6.35 (1H, d, 6.6)115.8, CH1.38 (1H, td, 12.6, 3.0)41.6, CH~2~2.05 (1H, dt, 12.6, 2.4)8162.4, C161.7, C39.3, C940.8, C40.5, C1.55 (1H, m) ^*c*^49.5, CH10165.5, C166.4, C39.3, C111.75 (1H, m) ^*c*^33.2, CH~2~1.78 (1H, m) ^*c*^33.1, CH~2~1.52 (1H, m) ^*c*^19.2, CH~2~1.94 (1H, m) ^*c*^1.94 (1H, m) ^*c*^1.65 (1H, m) ^*c*^121.59 (1H, m) ^*c*^29.3, CH~2~1.60 (1H, m) ^*c*^29.4, CH~2~1.57 (1H, m) ^*c*^33.8, CH~2~1.78 (1H, m) ^*c*^1.78 (1H, m) ^*c*^1.65 (1H, m)1338.4, C38.3, C38.0, C1444.5, C44.5, C158.4, C151.47 (1H, m) ^*c*^28.5, CH~2~1.49 (1H, m) ^*c*^28.5, CH~2~5.62 (1H, dd, 8.0, 3.0)117.1, CH1.54 (1H, m) ^*c*^1.59 (1H, m) ^*c*^161.44 (1H, m) ^*c*^36.3, CH~2~1.46 (1H, m) ^*c*^36.3, CH~2~1.74 (1H, m) ^*c*^38.0, CH~2~1.82 (1H, m) ^*c*^1.85 (1H, m) ^*c*^2.09 (1H, dd, 15.0, 3.0)1730.6, C30.6, C35.9, C181.53 (1H, m) ^*c*^44.1, CH1.56 (1H, m) ^*c*^44.1, CH1.16 (1H, dd, 13.2, 3.6)48.5, CH191.69 (1H, m) ^*c*^30.7, CH~2~1.72 (1H, m) ^*c*^30.8, CH~2~1.59 (1H, dd, 13.2, 3.6)32.4, CH~2~2.41 (1H, d, 15.6)2.42 (1H, d, 15.6)2.32 (1H, t, 13.2)2040.2, C40.1, C41.0, C211.36 (1H, td, 14.4, 3.0)29.6, CH~2~1.38 (1H, td, 13.8, 4.8)29.6, CH~2~1.51 (1H, m) ^*c*^29.8, CH~2~2.15 (1H, br d, 14.4)2.16 (1H, br d, 13.8)2.54 (1H, dt, 14.4, 3.6)220.95 (1H, br d, 14.4)34.6, CH~2~0.96 (1H, br d, 13.8)34.5, CH~2~1.20 (1H, m) ^*c*^35.8, CH~2~2.02 (1H, td, 14.4, 3.0)2.05 (1H, td, 13.8, 3.6)1.84 (1H, td, 14.4, 3.6)231.73 (3H, s)24.8, CH~3~1.63 (3H, s)28.2, CH~3~1.28 (3H, s)29.2, CH~3~241.13 (3H, s)17.6, CH~3~251.46 (3H, s)36.2, CH~3~1.43 (3H, s)35.9, CH~3~1.05 (3H, s)16.9, CH~3~261.21 (3H, s)22.7, CH~3~1.21 (3H, s)22.7, CH~3~1.13 (3H, s)26.2, CH~3~270.70 (3H, s)18.9, CH~3~0.74 (3H, s)18.9, CH~3~1.02 (3H, s)21.3, CH~3~281.07 (3H, s)31.5, CH~3~1.09 (3H, s)31.5, CH~3~0.96 (3H, s)30.2, CH~3~29182.7, C181.7, C182.2, C301.20 (3H, s)32.7, CH~3~1.22 (3H, s)32.7, CH~3~1.53 (3H, s)26.1, CH~3~OMe3.30 (3H, s)50.5, CH~3~3.30 (3H, s)50.9, CH~3~[^1]

Triregelolide B (**2**): white amorphous powder; \[*α*\]^21^ ~D~  + 119.09 (*c* 0.50, MeOH); UV (MeOH) *λ* ~max~ (log *ε*) 236 (3.24), 360 (3.42) nm; ^1^H (CDCl~3~, 600 MHz) and ^13^C (CDCl~3~, 150 MHz) NMR data, see [Table 1](#t0005){ref-type="table"}; HRESIMS *m/z* 467.2810 \[M − H\]^−^ (calcd for C~29~H~39~O~5~, 467.2803).

Triregeloic acid (**3**): white amorphous powder; \[*α*\]^21^ ~D~  − 12.27 (*c* 0.125, MeOH); UV (MeOH) *λ* ~max~ (log *ε*) 255 (2.25) nm; ^1^H (pyridine-*d* ~5~, 600 MHz) and ^13^C (pyridine-*d* ~5~, 150 MHz) NMR data, see [Table 1](#t0005){ref-type="table"}; HRESIMS *m/z* 471.3479 \[M − H\]^−^ (calcd for C~30~H~47~O~4~, 471.3480).

2.5. Cytotoxicity on human breast cancer cells MCF-7 {#s0035}
----------------------------------------------------

Human breast cancer cell lines (MCF-7) were purchased from American Type Culture Collection. The cells were cultured in Dulbecco\'s modified Eagle medium-F12 medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Invitrogen) and 1% penicillin-streptomycin (Sigma) at 37 °C in humidified atmosphere containing 5% CO~2~. Exponentially growing cells were plated in a 96-well microplate at a density of 5 × 10^3^ cells per well in 100 μL of culture medium and were allowed to adhere for 24 h before drug treatment. Then, the cells were treated with either fresh medium containing 0.1% DMSO or fresh medium containing 10 μM of triterpenes or paclitaxel (Taxol®), and incubated for another 24 h in a 5% CO~2~ humidified atmosphere at 37 °C. A volume of 10 μL MTT saline solution (5 mg/mL) was added into each well for further 4 h of incubation. Subsequently, 100 μL of lysing sodium dodecyl sulfate (SDS) were added into each well, and the 96-well microplate was kept overnight at room temperature. The absorbance of resulting solution in each well was colorimetrically determined at 570 nm by using a microplate reader (Infinite 200 PRO, Tecan). The inhibitory rate of compounds on cell proliferation was defined as (1 - absorbance of the drug-treated cells/ absorbance of the vehicle control cells) × 100%.

2.6. Statistical Analysis {#s0040}
-------------------------

Statistical analysis was performed using SPSS software, version 16.0 for Windows. The significance of difference among the experimental groups and controls was assessed by one-way ANOVA and Post hoc Bonferroni test. The results are presented as mean ± standard deviation (SD) from three independent experiments. Significance was accepted at a level of *p*  \< 0.05.

3. Results and discussion {#s0045}
=========================

The EtOAc-soluble fraction of methanolic extract of the stems of *T. regelii* was repeatedly subjected to silica gel and ODS columns, and then purified by preparative and/or semi-preparative HPLC to yield three new triterpenoids (**1**--**3**).

Compound **1** was obtained as white amorphous powder. Its HRESIMS showed a deprotonated molecular ion at *m/z* 467.2812 \[M − H\]^−^ (calcd for C~29~H~39~O~5~, 467.2803), corresponding to the molecular formula of C~29~H~40~O~5~ with ten degrees of unsaturation. Its UV spectrum exhibited absorption bands at 236 and 360 nm, suggesting the presence of a conjugated system in **1**. The ^1^H NMR data ([Table 1](#t0005){ref-type="table"}) showed characteristic signals for three olefinic protons \[δ~H~ 6.32 (1H, dd, *J*  = 6.6, 1.2 Hz, H-6), 5.98 (1H, d, *J*  = 6.6 Hz, H-7), 5.81 (1H, d, *J*  = 1.2 Hz, H-1)\], a methoxyl group \[δ~H~ 3.30 (3H, s)\], and six tertiary methyl groups \[δ~H~ 1.73 (3H, s, H~3~--23), 1.46 (3H, s, H~3~--25), 1.21 (3H, s, H~3~--26), 1.20 (3H, s, H~3~--30), 1.07 (3H, s, H~3~--28), 0.70 (3H, s, H~3~--27)\]. The ^13^C NMR spectroscopic data ([Table 1](#t0005){ref-type="table"}) displayed 29 carbon signals, including signals of a carboxylic carbon (*δ*c 182.7, C-29), a conjugated ester carbonyl carbon (δc 163.8, C-2), three double bonds, six quaternary carbons (including a ketal one), one methine, seven methylenes, and seven methyl groups (including an oxygenated one), which were accounted for five degrees of unsaturation. These characteristic data suggested **1** to be a dinor-friedelene derivative with five rings [@bb0110], [@bb0115], [@bb0120]. Comparison of the ^1^H and ^13^C NMR data of **1** with those of dzununcanone [@bb0110], [@bb0120], a 3,24-dinor-2,4-*seco*-friedelene triterpene, indicated both compounds bearing similar B-, C-, D- and E-rings. The downfield shift of C-29 (*δ*c 182.7) in **1** relative to that (*δ*c 179.1) in dzununcanone [@bb0110], [@bb0120] implied a carboxylic acid group present at C-29 in **1** instead of the methyl ester in dzununcanone. The remaining signals of **1** showed a olefinic carbon (*δ*c 110.3, C-1), a conjugated carbonyl carbon (*δ*c 163.8, C-2), a ketal carbon (*δ*c 103.8, C-4), a tertiary methyl (*δ*c 24.8, C-23) and a methoxyl (*δ*c 50.5) groups. The upfield shift of the C-2 carbonyl (*δ*c 163.8) in **1** relative to that (*δ*c 166.1) in dzununcanone revealed that an *α*,*β*-unsaturated *δ*-lactone ring was formed between C-2 and C-4 in **1**, accounting for the remaining one degree of unsaturation. Both the methoxyl and the tertiary methyl groups were assigned at C-4, as deduced from HMBC correlations from their protons to C-4 (*δ* ~C~ 103.8) in **1**. Thus, the planar structure of **1** was established as a 2, 4-esterified derivative of dzununcanone, which was further confirmed by ^1^H −  ^1^H COSY and HMBC correlations ([Fig. 2](#f0010){ref-type="fig"}A).

The relative configuration of **1** was determined by analysis of ROESY spectrum ([Fig. 2](#f0010){ref-type="fig"}B). The observed key correlation between C-4 methoxy protons and H~3~--25*β* indicated that the methoxyl group at C-4 was *β*-oriented. The remaining stereogenic centers in **1** were assigned as the same relative configurations with those in dzununcanone, as evidenced from the important ROESY correlations of H~3~--25/H~3~--26, H~3~--26/H~3~--28, and H~3~--28/H~3~--30. Therefore, the structure of **1** was characterized as shown in [Fig. 1](#f0005){ref-type="fig"} , and given a trivial name of triregelolide A.Fig. 1The chemical structures of compounds **1--23**, dzununcanone and esculentoic acid A.Fig. 1Fig. 2The ^1^H − ^1^H COSY, key HMBC (A) and selected ROESY (B) correlations of **1**.Fig. 2

Compound **2** has the same molecular formula of C~29~H~40~O~5~ as that of **1** based on HRESIMS data (*m*/*z* 467.2810 \[M − H\]^−^, calcd for C~29~H~39~O~5~, 467.2803). The ^1^H and ^13^C NMR spectroscopic data ([Table 1](#t0005){ref-type="table"}) of **2** are closely similar to those of **1** except for the downfield shifts of C-4 and C-23 (*δ* ~C~ 105.6 and 28.2) relative to those (*δ* ~C~ 103.8 and 24.8) in **1**. These data were indicative of different configuration of the C-4 stereogenic center of both compounds. Moreover, a key ROESY correlation between H~3~--23 and H~3~--25*β* was observed, revealing an *α*-orientation of the methoxy group at C-4. Therefore, the structure of **2** was elucidated as a 4-epimer of **1**, and given a trivial name of triregelolide B.

Compound **3** was obtained as amorphous powder. The molecular formula was determined as C~30~H~48~O~4~, based on its HRESIMS data (*m/z* 471.3479 \[M − H\] ^−^, calcd for C~30~H~47~O~4~, 471.3480). The ^1^H NMR data ([Table 1](#t0005){ref-type="table"}) displayed the presence of an olefinic proton \[*δ* ~H~ 5.62 (1H, dd, *J*  = 8.0, 3.0 Hz, H-15)\], two oxygenated methine protons \[*δ* ~H~ 4.13 (1H, td, *J*  = 9.6, 4.2 Hz, H-2) and 3.39 (1H, d, *J*  = 9.6 Hz, H-3)\], and seven tertiary methyl groups \[*δ* ~H~ 1.53 (3H, s, H~3~--30), 1.28 (3H, s, H~3~--23), 1.13 (6H, s, H~3~--24 and H~3~--26), 1.05 (3H, s, H~3~--25), 1.02 (3H, s, H~3~--27) and 0.96 (3H, s, H~3~--28)\]. The ^13^C NMR data ([Table 1](#t0005){ref-type="table"}) of **3** showed 30 carbon signals, which were ascribed to a carboxylic group (*δ* ~C~ 182.2, C-29), two olefinic carbons \[*δ* ~C~ 158.4 (C-14) and 117.1 (C-15)\], five methines (including two oxygenated ones), six quaternary carbons, nine methylenes, and seven methyl carbons by DEPT and HMBC experiments. These characteristic signals indicated that **3** was a taraxerene-type triterpene [@bb0125], [@bb0130], [@bb0135]. The ^1^H and ^13^C NMR data of **3** were very similar to those of esculentoic acid A [@bb0130] isolated from *Manihot esculenta*, except for the presence of an additional oxygenated methine \[*δ* ~H~ 4.13 (1H, td, *J*  = 9.6, 4.2 Hz, H-2); *δ* ~C~ 68.6\] and the absence of a methylene signals (*δ* ~H~ 1.78 and 1.60; *δ* ~C~ 25.3) in esculentoic acid A [@bb0130]. The downfield shift of H-2 at *δ* ~H~ 4.13 suggested hydroxylation of C-2 in **3** compared to those (*δ* ~H~ 1.78 and 1.60) in esculentoic acid A [@bb0130]. The coupling constant of 9.6 Hz between H-2 and H-3 (*J* ~2,\ 3~) indicated a 2,3-trans diaxial relationship of the above two protons in **3**, whereas the H-3 was in a equatorial bond in esculentoic acid due to a smaller *J* ~2,\ 3~ of 2.8 Hz. The key NOESY correlations of H-2/H~3~--25*β*, and H-3/H-5*α* suggested an *α-*oriented hydroxyl group at C-2 and a *β-*oriented hydroxyl group at C*-*3 in **3**. Thus, the structure of **3** was determined as 2*α*, 3*β*-dihydroxytaraxer-14-ene-29-oic acid, and named triregeloic acid.

In addition, twenty known triterpenoids were also isolated and identified as NST6A (**4**) [@bb0140], celastrol (**5**) [@bb0145], [@bb0150], 22*β*-hydroxy-tingenone (**6**) [@bb0155], triptocalline A (**7**) [@bb0160], polpunonic acid (**8**) [@bb0165], orthophenic acid (**9**) [@bb0155], demethylzeylasteral (**10**) [@bb0150], wilforol A (**11**) [@bb0155], regelin D (**12**) [@bb0095], triptotriterpenic acid B (**13**) [@bb0170], [@bb0175], abrusgenic acid (**14**) [@bb0170], [@bb0180], wilforlide A (**15**) [@bb0155], [@bb0185], wilforlide B (**16**) [@bb0185], triptocallic acid A (**17**) [@bb0190], regelinol (**18**) [@bb0080], regelin C (**19**) [@bb0095] , regelin (**20**) [@bb0095], [@bb0195], dulcioic acid (**21**) [@bb0155], tripterygic acid A (**22**) [@bb0200], demethylregelin (**23**) [@bb0155], based on analyses of their NMR spectroscopic data and comparisons with those in the literatures. Ten triterpenes (**4**, **7**, **8**, **10**, **13**, **14**, **17**, **21**--**23**) were isolated from *T. regelii* for the first time.

Cytotoxic effects of nine selected triterpenes (**3, 5**, **6**, **8**--**10**, **14**, **16**, **21**) were evaluated against human breast cancer MCF-7 cells at a concentration of 10 μM ([Table 2](#t0010){ref-type="table"} ), the other triterpenes were not conducted cytotoxic bioassay due to a limited amount obtained from *T. regelii*. Taxol was used as a positive control drug. As a result, triterpenes **3**, **5**, **6**, **8**, **9**, **10**, **14** and **16** showed inhibitory effects on the proliferation of MCF-7 cells by 24.1%, 69.6%, 72.8%, 21.6%, 23.1%, 43.3%, 25.5% and 23.5% (*p*  \< 0.05) at a concentration of 10 μM, respectively. Triterpenes **5** and **6** exhibited more potent (*p*  \< 0.001) cytotoxic effects than taxol (with an inhibitory rate of 35.0%) at 10 μM drug concentration.Table 2Cytotoxic effects of nine triterpenes and taxol on human breast cancer MCF-7 cells.Table 2Compounds [a](#tf0010){ref-type="table-fn"}Inhibitory rate (%) [b](#tf0015){ref-type="table-fn"}Taxol35.0 ± 5.06**3**24.1 ± 2.21[⁎](#tf0005){ref-type="table-fn"}**5**69.6 ± 0.75[⁎](#tf0005){ref-type="table-fn"}**6**72.8 ± 0.53[⁎](#tf0005){ref-type="table-fn"}**8**21.6 ± 1.66[⁎](#tf0005){ref-type="table-fn"}**9**23.1 ± 1.31[⁎](#tf0005){ref-type="table-fn"}**10**43.3 ± 2.21[⁎](#tf0005){ref-type="table-fn"}**14**25.5 ± 1.45[⁎](#tf0005){ref-type="table-fn"}**16**23.5 ± 3.12[⁎](#tf0005){ref-type="table-fn"}**21**7.2 ± 5.07[^2][^3][^4]
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[^1]: ^*a*^ Measured in CDCl~3~. ^*b*^ Measured in pyridine-*d*~5~. ^*c*^ The overlapped signals were assigned from ^1^H − ^1^H COSY, HSQC, and HMBC spectra.

[^2]: All compounds except for **21**, showed significant (*p* \< 0.05) inhibitory effects on the proliferation of MCF-7 cells compared to the vehicle control group. The value of *p* \< 0.001 when statistical comparison was conducted between either compound **5** or **6** with taxol.

[^3]: Other triterpenes were not evaluated for cytotoxicity due to the limited amount obtained.

[^4]: The inhibitory rate (%) on MCF-7 cells was determined at a drug concentration of 10 μM.
